Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) COGS-to-Revenue : 0.52 (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Hainan Huluwa Pharmaceutical Group Co COGS-to-Revenue?

Hainan Huluwa Pharmaceutical Group Co's Cost of Goods Sold for the three months ended in Mar. 2024 was ¥225 Mil. Its Revenue for the three months ended in Mar. 2024 was ¥430 Mil.

Hainan Huluwa Pharmaceutical Group Co's COGS to Revenue for the three months ended in Mar. 2024 was 0.52.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Hainan Huluwa Pharmaceutical Group Co's Gross Margin % for the three months ended in Mar. 2024 was 47.77%.

Hainan Huluwa Pharmaceutical Group Co COGS-to-Revenue Historical Data

The historical data trend for Hainan Huluwa Pharmaceutical Group Co's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hainan Huluwa Pharmaceutical Group Co COGS-to-Revenue Chart

Hainan Huluwa Pharmaceutical Group Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.38

0.40

0.42

0.47

Hainan Huluwa Pharmaceutical Group Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial															0.46	0.50	0.50	0.45	0.52

Hainan Huluwa Pharmaceutical Group Co COGS-to-Revenue Calculation

Hainan Huluwa Pharmaceutical Group Co's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	899.832	/	1905.182
	=	0.47

Hainan Huluwa Pharmaceutical Group Co's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	224.817	/	430.405
	=	0.52

Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Hainan Huluwa Pharmaceutical Group Co's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	224.817 / 430.405
	=	47.77 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Hainan Huluwa Pharmaceutical Group Co COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hainan Huluwa Pharmaceutical Group Co's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hainan Huluwa Pharmaceutical Group Co Ltd (SHSE:605199) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

N/A

Address

No. 8, Yaogu 4th Road, Phase II, Yaogu Industrial Park, Haikou National High-tech Zone, Hainan Province, Haikou, CHN, 570300

Website

http://www.huluwayaoye.com

Hainan Huluwa Pharmaceutical Group Co Ltd is engaged in production and sales of Chinese patent medicines and chemical drugs. The company produces medicines for children's respiratory and digestive systems. Its products include star products, calabash, gourd dad, and gourd mom.

Hainan Huluwa Pharmaceutical Group Co (SHSE:605199) Headlines

No Headlines